These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 19590589)
21. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. King AB Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433 [TBL] [Abstract][Full Text] [Related]
22. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Ilag LL; Kerr L; Malone JK; Tan MH Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388 [TBL] [Abstract][Full Text] [Related]
23. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Raskin P; Gylvin T; Weng W; Chaykin L Diabetes Metab Res Rev; 2009 Sep; 25(6):542-8. PubMed ID: 19565569 [TBL] [Abstract][Full Text] [Related]
24. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Fadini GP; de Kreutzenberg SV; Mariano V; Boscaro E; Bertolini F; Mancuso P; Quarna J; Marescotti M; Agostini C; Tiengo A; Avogaro A Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861 [TBL] [Abstract][Full Text] [Related]
25. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. Chapman TM; Perry CM BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219 [TBL] [Abstract][Full Text] [Related]
26. Higher dose requirements with insulin detemir in type 2 diabetes--three cases and a review of the literature. Swinnen SG; DeVries JH Diabetes Res Clin Pract; 2009 May; 84(2):e24-6. PubMed ID: 19251336 [TBL] [Abstract][Full Text] [Related]
27. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B; Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis. Rezaei S; Taheri A; Taheri S; Kasirzadeh S; Fatemi B; Sorato MM Expert Rev Clin Pharmacol; 2022 Jun; 15(6):767-777. PubMed ID: 35579011 [TBL] [Abstract][Full Text] [Related]
29. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects? Valensi P; Cosson E Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896 [TBL] [Abstract][Full Text] [Related]
30. Basal insulins: Pharmacological properties and patient perspectives. Abrahamson MJ Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887 [TBL] [Abstract][Full Text] [Related]
31. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007 [TBL] [Abstract][Full Text] [Related]
32. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S; Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846 [TBL] [Abstract][Full Text] [Related]
33. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Lüddeke HJ; Sreenan S; Aczel S; Maxeiner S; Yenigun M; Kozlovski P; Gydesen H; Dornhorst A; Diabetes Obes Metab; 2007 May; 9(3):428-34. PubMed ID: 17391171 [TBL] [Abstract][Full Text] [Related]
34. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study. Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719 [TBL] [Abstract][Full Text] [Related]
35. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center. Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170 [TBL] [Abstract][Full Text] [Related]
36. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Swinnen SG; Dain MP; Aronson R; Davies M; Gerstein HC; Pfeiffer AF; Snoek FJ; Devries JH; Hoekstra JB; Holleman F Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301 [TBL] [Abstract][Full Text] [Related]
37. Insulin glargine in the treatment of type 1 and type 2 diabetes. Barnett AH Vasc Health Risk Manag; 2006; 2(1):59-67. PubMed ID: 17319470 [TBL] [Abstract][Full Text] [Related]
38. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Baxter MA Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296 [TBL] [Abstract][Full Text] [Related]
39. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus. Hemmingsen B; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147 [TBL] [Abstract][Full Text] [Related]
40. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes. Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]